The two active ingredients occupy distinct pharmacological territories. Brexpiprazole, chemically 7-[4-[4-(1-benzothiophen-4-yl)piperazin-1-yl]butoxy]-1H-quinolin-2-one, is an atypical antipsychotic classified as a serotonin-dopamine activity modulator. It partially activates D2 dopamine and serotonin 1A receptors and binds strongly to serotonin, dopamine, and alpha-adrenergic receptors; the United States Food and Drug Administration approved it on July 10, 2015. Escitalopram oxalate, structurally (1S)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3H-2-benzofuran-5-carbonitrile oxalate, belongs to the selective serotonin reuptake inhibitor class and treats depression and anxiety by increasing serotonergic activity in the brain. The combination of the two agents was approved in 2014 and has been studied in clinical trials for mood disorders, which makes reliable analytical tools for the pair increasingly important.

To build the method, the team used a Shimadzu semi-automatic liquid chromatograph equipped with a photodiode array detector and Win Chrome software, injecting samples through a microliter syringe onto a reversed-phase C18 column measuring 250 millimeters by 4.6 millimeters with five-micron particles. Raw materials were supplied as gift samples by Virdev Pharma of Palsana and Sun Pharmaceutical Industries of Panoli, and the researchers prepared a synthetic mixture mimicking a combined dosage form at a ratio of 40 micrograms per milliliter of brexpiprazole to 120 micrograms per milliliter of escitalopram oxalate. Because no commercial product exists, the synthetic mixture served as the practical test bed for the entire validation exercise.

Optimization of the chromatographic conditions revealed that a mobile phase of methanol and phosphate buffer, adjusted to pH 4.0 with orthophosphoric acid and mixed in a 55:45 volume ratio, delivered the best performance. Elution ran in isocratic mode at a flow rate of one milliliter per minute, with detection at 214 nanometers and a total run time of ten minutes. Under these conditions brexpiprazole eluted at 2.7 minutes and escitalopram at 7.0 minutes in the reported system suitability work, with symmetrical peak shapes, theoretical plate counts above 2000, and tailing factors at or below 2.0. The separation logic is rooted in the chemistry of the two molecules: both carry basic functional groups and exist predominantly in protonated form at pH 4.0, but brexpiprazole is considerably more lipophilic, with a log P of roughly 4.7 to 5.0 compared with 3.5 to 4.0 for escitalopram. That difference governs how strongly each analyte interacts with the nonpolar C18 stationary phase and therefore dictates the elution order.

Validation followed the International Council for Harmonization guideline Q2(R2), the current global standard for analytical procedure validation. Linearity was assessed at five concentration levels with six replicates each, spanning 0.5 to 3 micrograms per milliliter for brexpiprazole and 5 to 30 micrograms per milliliter for escitalopram oxalate. Calibration curves returned correlation coefficients exceeding 0.999 for both drugs, indicating an exceptionally straight relationship between peak area and concentration across the working ranges. Accuracy was confirmed through standard addition and recovery studies at 80, 100, and 120 percent spiking levels, with satisfactory recoveries demonstrating that common formulation excipients do not interfere with quantification.

Precision, the method’s ability to produce consistent results, was evaluated in both intraday and interday experiments. Three standard solutions of different concentrations were injected repeatedly within a single day and again across three consecutive days, and the relative standard deviation stayed below 2.0 percent throughout. Specificity was demonstrated by analyzing blank mobile phase and sample solutions, with no interfering peaks appearing at the retention times of either analyte. Sensitivity limits were calculated from the standard deviation of the response and the slope of the calibration curve using the ICH equations LOD equals 3.3 times sigma over S and LOQ equals 10 times sigma over S, yielding low detection and quantification limits that confirm the method’s suitability for trace-level work. Robustness testing deliberately introduced small variations in flow rate, mobile phase composition, pH, and detection wavelength, while ruggedness was probed through changes of analyst and column, with retention times remaining stable in all cases.

When the optimized method was applied to the synthetic mixture containing 2 micrograms per milliliter of brexpiprazole and 20 micrograms per milliliter of escitalopram oxalate, the assay results were striking: 99.67 percent recovery for brexpiprazole with a relative standard deviation of 0.308 percent, and 99.94 percent for escitalopram oxalate with a relative standard deviation of 0.227 percent. These figures indicate that the procedure measures the actual content of a mixture with near-perfect fidelity and minimal scatter, exactly the profile a quality control laboratory needs when certifying batches of a finished product.

What distinguishes this study from a routine validation exercise is its systematic greenness assessment. The authors evaluated the method with three complementary tools drawn from Green Analytical Chemistry. The AGREE metric, which scores a procedure against the twelve principles of green analytical chemistry, returned 0.71, indicating good compliance. The Blue Applicability Grade Index, which weighs practical applicability alongside sustainability, scored 72.5, and the Complex GAPI pictogram, which accounts for reagent hazards, energy consumption, and waste generation across the whole procedure, scored 81. The environmental arithmetic is straightforward: each ten-minute analysis consumes roughly ten milliliters of mobile phase, split into 5.5 milliliters of methanol and 4.5 milliliters of water, and generates only about ten milliliters of waste. The simple methanol-water system avoids more hazardous solvents entirely, and the short run time keeps energy demand low.

The team also extended the evaluation into White Analytical Chemistry, a framework that mirrors the twelve green principles but adds two further pillars: red for analytical performance and blue for practical and economic factors. By reporting the arithmetic means for the red, green, and blue sections separately, the authors acknowledged that a truly sustainable method must be green without sacrificing accuracy, precision, or cost-effectiveness. Their conclusion was that the method is acceptably green and suitable for sustainable routine applications without compromising performance, with only minor limitations remaining.

The practical significance of the work lies in its readiness for routine use. Because the method is the first created for rapid analysis of this binary mixture at a single wavelength, and because it passed every ICH Q2(R2) validation parameter with strong margins, pharmaceutical laboratories could adopt it directly for stability studies, formulation development, and batch release testing of any future brexpiprazole-escitalopram combination product. The combination of a ten-minute run time, modest solvent consumption, sub-2-percent variability, and recoveries near 100 percent represents a template for how modern analytical chemistry can serve drug development while shrinking its own environmental footprint, a balance that regulators and manufacturers alike are increasingly demanding.

Subject of Research: Development and greenness assessment of a validated RP-HPLC method for simultaneous estimation of brexpiprazole and escitalopram oxalate

Article Title: Development, validation, and greenness assessment of a green RP-HPLC method for rapid simultaneous estimation of brexpiprazole and escitalopram oxalate in combined dosage form

Article References: Solanki, D., & Dedania, Z. (2026). Development, validation, and greenness assessment of a green RP-HPLC method for rapid simultaneous estimation of brexpiprazole and escitalopram oxalate in combined dosage form. Discover Chemistry, 3(1), Article 444. https://doi.org/10.1007/s44371-026-00887-z

Image Credits: AI Generated

DOI: 10.1007/s44371-026-00887-z

Keywords: RP-HPLC, brexpiprazole, escitalopram oxalate, method validation, ICH Q2(R2), green analytical chemistry, AGREE metric, pharmaceutical analysis, liquid chromatography, antidepressants, quality control, sustainable chemistry

The review begins with the established drug classes. Cholinesterase inhibitors such as donepezil, rivastigmine and galantamine, together with the N-methyl-D-aspartate receptor antagonist memantine, continue to deliver small but statistically significant and clinically meaningful improvements in cognition and function. A meta-analysis of 43 randomized clinical trials encompassing more than 16,000 patients, cited in the review, quantifies both the efficacy and the substantial discontinuation rates that complicate real-world use. What is new, however, is the emerging biomarker dimension. Stratified analyses now suggest that individuals with biochemically confirmed Alzheimer pathology, verified through amyloid positron emission tomography or cerebrospinal fluid markers, respond more robustly to these agents than patients whose cognitive impairment arises from other mechanisms. Studies of amyloid PET-negative mild cognitive impairment show markedly attenuated cognitive responses to cholinesterase inhibitors, and positron emission tomography work even hints that these drugs may influence tau pathology within the Alzheimer disease continuum. The implication is profound: the era of prescribing cognitive enhancers on clinical impression alone may be drawing to a close, replaced by biomarker-informed precision symptomatic therapeutics.

Beyond the cholinergic and glutamatergic mainstream, the review charts a strikingly diverse pipeline of next-generation symptomatic agents. Selective muscarinic receptor agonism, a strategy first explored with xanomeline in the 1990s, has returned to prominence with modern M1-selective compounds such as HTL0018318, which showed preliminary pharmacodynamic activity in mild-to-moderate Alzheimer disease, and with xanomeline-based programs now being tested for Alzheimer-related psychosis in the ADEPT-5 trial. Multitarget agents are advancing in parallel: blarcamesine, which modulates the sigma-1 receptor and other pathways, reported phase IIB/III results in early Alzheimer disease, while masupirdine, a selective serotonergic 5-HT6 antagonist, showed exploratory signals on agitation, aggression and psychosis in moderate disease. Neurotrophic modulation represents another frontier, with positive allosteric modulators of neurotrophin receptors under development to support synaptic resilience, and brain-derived neurotrophic factor gene therapy being explored as a longer-term strategy for neurodegeneration.

Drug repurposing has emerged as a particularly pragmatic route to broader symptomatic benefit. The review highlights a Delphi consensus process and stakeholder consultation that prioritized existing medicines with plausible mechanisms and safety profiles for Alzheimer disease, alongside work identifying synergistic combinations of repurposed treatments. The logic is compelling: established drugs with decades of safety data can be recombined rationally to hit multiple neurotransmitter and circuit-level systems simultaneously, potentially achieving additive or synergistic effects that single agents cannot. Combination therapy itself is gaining formal traction, with the EU/US Clinical Trials on Alzheimer’s Disease task force articulating frameworks for testing cholinesterase inhibitor plus memantine regimens and, ultimately, pairing symptomatic agents with disease-modifying antibodies such as lecanemab and donanemab, whose approvals have changed the therapeutic context in which symptomatic care is delivered.

On the non-pharmacological side, the evidence base has matured considerably. Cognitive training, structured physical exercise, cognitive stimulation therapy and multimodal lifestyle programmes all show small-to-moderate benefits, with the strongest and most consistent effects observed in people with mild cognitive impairment. Computerized cognitive training meta-analyses demonstrate measurable gains in memory and general cognition, and comparative trials have even suggested that crossword puzzles may outperform computerized games on some outcomes. Exercise research, synthesized through network meta-analyses, points to benefits for executive function, activities of daily living and potentially the capacity for independent living, with aerobic, resistance and multicomponent regimens each contributing. The landmark FINGER trial, which combined diet, exercise, cognitive training and vascular risk monitoring, and its American counterpart US POINTER, which compared structured against self-guided multidomain lifestyle intervention, have established that comprehensive lifestyle programmes can protect global cognition in at-risk older adults, findings now being translated into public health policy.

Cognitive stimulation therapy deserves particular attention as one of the few non-drug interventions with evidence at the level of established dementia, not merely its prodrome. Systematic reviews and meta-analyses of randomized controlled trials using the original protocol show benefits for cognition and quality of life in mild-to-moderate disease, and emerging work extends the approach to mild cognitive impairment. Yet the review is candid about the implementation gap. Scalability, workforce training, delivery fidelity and real-world adherence remain formidable barriers, particularly in residential aged care settings where systematic reviews document persistent obstacles to embedding evidence-based non-pharmacological therapies. Non-invasive brain stimulation, including repetitive transcranial magnetic stimulation and transcranial direct current stimulation, is profiled as an adjunctive technology with encouraging meta-analytic signals for cognition and daily functioning, though heterogeneity across protocols tempers enthusiasm.

The most clinically burdensome domain, the review argues, is neuropsychiatric symptomatology. Agitation, depression, apathy, psychosis and sleep disturbance affect the substantial majority of people with Alzheimer disease over the course of illness, driving caregiver distress, institutionalization and reduced quality of life more powerfully than cognitive decline itself. Here the evidence favours personalized psychosocial interventions. The WHELD programme, a factorial cluster-randomized trial combining person-centred care training, tailored social interaction and exercise, and antipsychotic review, reduced agitation and antipsychotic prescribing in nursing homes, and its digital adaptation has since been tested in a randomized controlled trial. Brief operationalized psychosocial interventions for agitation and psychosis, systematic individualized approaches that identify the unmet needs driving behavioural symptoms, and structured strategies such as the DICE framework for caregiver training all demonstrate meaningful reductions in agitation and depression without pharmacological risk. Even treating pain, as a cluster-randomized trial showed, substantially reduces behavioural disturbance in nursing home residents with dementia.

Where drugs are required, the safety calculus is unfavourable for older agents. Atypical antipsychotics offer only modest efficacy against agitation and psychosis while carrying elevated risks of stroke, mortality, cognitive worsening and sedation, findings documented across the CATIE-AD trial, Cochrane reviews and the long-term DART-AD follow-up, which showed sustained excess mortality associated with continued antipsychotic exposure. Against this backdrop, newer agents represent genuine, if incremental, progress. Brexpiprazole, now approved for agitation associated with dementia due to Alzheimer disease, demonstrated significant benefit in two 12-week phase trials and in post hoc analyses of clinically relevant subgroups, with a more favourable metabolic and motor safety profile than predecessors. The dextromethorphan-quinidine combination AXS-05 showed relapse-prevention efficacy in the phase 3 ACCORD trial and became the first non-antipsychotic approved in the United States for dementia-related agitation. Pimavanserin, an inverse agonist at serotonin 5-HT2A receptors, showed significant benefit for dementia-related psychosis in a pivotal trial and phase 2 data in Alzheimer disease psychosis, while escitalopram achieved a positive phase 3 result for agitation, contrasting with the negative mirtazapine findings from the SYMBAD trial. Methylphenidate, meanwhile, offers a modestly effective option for apathy in the ADMET 2 trial.

The review’s forward-looking synthesis is unambiguous about what must change. Future progress will depend on biomarker-informed patient selection, increasingly enabled by blood-based biomarkers now moving into clinical implementation; on the integration of circuit-level measures that connect molecular mechanisms to network dysfunction; on rational combination strategies that span pharmacological and non-pharmacological modalities rather than testing interventions in isolation; and on the adoption of patient-centred outcomes such as goal attainment, quality of life and independence rather than narrow rating-scale endpoints. Symptomatic therapies, the authors conclude, will remain essential for improving quality of life in people with Alzheimer disease even as disease-targeted therapies gradually reshape disease trajectories. In an era captivated by amyloid clearance, the humble work of relieving symptoms, sharpening cognition, preserving function and calming distress is being reimagined with a precision and ambition that may ultimately matter just as much to patients and the families who love them.

Subject of Research: Current evidence and future directions for pharmacological and non-pharmacological symptomatic treatment of Alzheimer disease

Article Title: Symptomatic treatment for Alzheimer disease: current evidence and future directions

Article References: Ballard, C., Doherty, P., Ismail, Z., Corbett, A., & Cummings, J. L. (2026). Symptomatic treatment for Alzheimer disease: current evidence and future directions. Nature Reviews Neurology. https://doi.org/10.1038/s41582-026-01260-5

Image Credits: AI Generated

DOI: 10.1038/s41582-026-01260-5

Keywords: Alzheimer disease, symptomatic treatment, cholinesterase inhibitors, memantine, neuropsychiatric symptoms, cognitive stimulation therapy, physical exercise, brexpiprazole, pimavanserin, biomarkers, drug repurposing, combination therapy